About Enterome

We are a clinical stage biopharmaceutical company developing first in class drugs based on our unique ability to de-code molecular interactions in the gut microbiome impacting human health.

We have developed two highly promising pipelines of clinical and pre-clinical candidates with a focus on cancer and auto-immune diseases:

– OncoMimics™: highly effective, off-the-shelf immunotherapies against cancers (EO2401, EO2463). EO2401 is in Phase 1/2 clinical trials in patients with glioblastoma and adrenal tumors. EO2463 is in a Phase 1/2 clinical trial for indolent non-Hodgkin B-cell lymphomas.

– EndoMimics™: a new generation of biologics targeting inflammatory diseases (EB1010) and metabolic diseases.

In addition, Enterome’s clinical candidate sibofimloc (also referred to as TAK-018) is advancing through a Phase 2 clinical trial in post-operative Crohn’s disease. Sibofimloc has been partnered with Takeda globally, with Enterome retaining a significant profit share in the US.